Free Trial
NASDAQ:TLIS

Talis Biomedical (TLIS) Stock Price, News & Analysis

Talis Biomedical logo
$1.69 -0.02 (-1.42%)
(As of 05:39 PM ET)

About Talis Biomedical Stock (NASDAQ:TLIS)

Key Stats

Today's Range
$1.69
$1.71
50-Day Range
$1.56
$2.15
52-Week Range
$1.37
$9.60
Volume
9,181 shs
Average Volume
13,311 shs
Market Capitalization
$3.08 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Talis Biomedical Corporation operates as a molecular diagnostic company, focusing on developing medical devices for infectious diseases and other conditions at the point of care in the United States. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Chicago, Illinois.

Receive TLIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Talis Biomedical and its competitors with MarketBeat's FREE daily newsletter.

TLIS Stock News Headlines

Talis Biomedical Corp Ordinary Shares
Trump won. Buy this coin now.
Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.
Why Is Talis Biomedical (TLIS) Stock Down 52% Today?
See More Headlines

TLIS Stock Analysis - Frequently Asked Questions

Talis Biomedical's stock was trading at $7.45 at the beginning of the year. Since then, TLIS stock has decreased by 77.3% and is now trading at $1.69.
View the best growth stocks for 2024 here
.

Talis Biomedical Co. (NASDAQ:TLIS) issued its quarterly earnings results on Tuesday, March, 15th. The company reported ($18.90) earnings per share for the quarter, beating the consensus estimate of ($19.20) by $0.30. Talis Biomedical had a negative net margin of 5,784.73% and a negative trailing twelve-month return on equity of 79.74%.

Talis Biomedical's stock reverse split before market open on Thursday, July 6th 2023. The 1-15 reverse split was announced on Thursday, July 6th 2023. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 6th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

Talis Biomedical (TLIS) raised $150 million in an IPO on Friday, February 12th 2021. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, BofA Securities and Piper Sandler acted as the underwriters for the IPO and BTIG was co-manager.

Top institutional investors of Talis Biomedical include BML Capital Management LLC (13.66%).
View institutional ownership trends
.

Shares of TLIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that Talis Biomedical investors own include Bloom Energy (BE), SoFi Technologies (SOFI), Athenex (ATNX), Alkaline Water (WTER), Milestone Scientific (MLSS), TherapeuticsMD (TXMD) and Affirm (AFRM).

Company Calendar

Last Earnings
3/15/2022
Today
11/21/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Analytical instruments
Sub-Industry
Measuring And Control Equipment
Current Symbol
NASDAQ:TLIS
Fax
N/A
Employees
260
Year Founded
N/A

Profitability

Net Income
$-62,010,000.00
Net Margins
-5,784.73%
Pretax Margin
-12,506.37%

Debt

Sales & Book Value

Annual Sales
$2.13 million
Book Value
$37.95 per share

Miscellaneous

Free Float
984,000
Market Cap
$3.08 million
Optionable
No Data
Beta
1.56
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

This page (NASDAQ:TLIS) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners